You are here

  • Home
  • Archive
  • Volume 26, Issue 6
  • Validation of Revised FIGO Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum Based on a Single Histological Type

Article Text

Article menu
Download PDFPDF
Ovarian Cancer
Validation of Revised FIGO Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum Based on a Single Histological Type
  1. Tayfun Toptas, MD,
  2. Elif Pestereli, MD,
  3. Onur Erol, MD,
  4. Selen Bozkurt, PhD,
  5. Gulgun Erdogan, MD and
  6. Tayup Simsek, MD
  1. * Division of Gynecologic Oncological Surgery, Department of Obstetrics and Gynecology, Antalya Research and Training Hospital;
  2. † Division of Gyneco-pathology, Department of Pathology,
  3. ‡ Departmentof Biostatistics and Medical Informatics, and
  4. § Division of Gynecologic Oncological Surgery, Department of Obstetrics and Gynecology, Akdeniz University School of Medicine, Antalya, Turkey.
  1. Address correspondence and reprint requests to Tayfun Toptas MD, Antalya Research and Training Hospital, D-Blok, Kat 2, 07070, Antalya, Turkey. E-mail: drttoptas{at}gmail.com.

Abstract

Objective This study aimed to evaluate the prognostic significance of revised International Federation of Gynecology and Obstetrics (FIGO2013) staging classification for cancer of the ovary, fallopian tube, and peritoneum in patients exhibiting high-grade serous histology.

Methods Clinical records of patients with high-grade serous carcinoma who underwent primary surgery between 2007 and 2012 were reviewed retrospectively. Patients were reclassified according to the FIGO2013 criteria. Progression-free survival (PFS) and overall survival (OS) were calculated for each stage using Kaplan-Meier estimates and compared with the log-rank test.

Results In total, 125 patients were included in the analysis. The distribution of the study cohort according to the revised classification was as follows; stage I, 6 patients; stage II, 9 patients; stage III, 85 patients; and stage IV, 25 patients. Median follow-up time was 36 months (95% confidence interval [CI], 3–110). The median PFS and OS were 14 months (95% CI, 12.4–15.6) and 60 months (95% CI, 47.0–72.9), respectively. Both PFS and OS were significantly different among stages I, II, III, and IV (P < 0.01). Subgroup analyses for stage III disease also revealed significant differences in survival. The median PFS for stages IIIA1, IIIB, and IIIC was 56, 46, and 16 months, respectively (P < 0.01), and the median OS was 104, 95, and 60 months, respectively (P = 0.03). The outcomes of patients with stage IV disease differed slightly but nonsignificantly according to new substages. The median PFS for stages IVA and IVB was 12 and 6 months, respectively (hazard ratio, 1.16; 95% CI, 0.48–2.79; P = 0.72), and the median OS was 41 and 24 months, respectively (hazard ratio, 1.62; 95% CI, 0.58–4.55; P = 0.35). The study sample was insufficient in size for subgroup analyses in stages I and II.

Conclusions The revised FIGO2013 staging system is highly prognostic for discriminating outcomes of patients with high-grade serous carcinoma across stages I to IV, in subgroups of stage III, but not in subgroups of stage IV.

  • Cancer staging
  • New classification
  • Ovarian cancer
  • High-grade serous carcinoma

https://doi.org/10.1097/IGC.0000000000000736

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • The authors declare no conflicts of interest.